Revenues in the third quarter of 2005 reflected lower...

Revenues in the third quarter of 2005 reflected lower prescription growth and increased competition in key therapeutic markets in the U.S., such as the lipid-lowering market, where the rate of growth in the third quarter declined significantly versus the first half of the year; and the erectile dysfunction market, which has been in decline compared to 2004.